Patient-reported outcomes (PROs) capture symptoms, functioning, quality of life, treatment burden and priorities directly from patients. Their integration into Molecular Tumor Board (MTB)-guided care remains limited and particularly challenging, as recommendations often involve off-label therapies, sparse evidence and...
L. Gräßel, S. Yacob, C. Strantz et al.· npj Precision Oncology· 0 citations
Immune checkpoint inhibitors (ICIs) and BRAF/MEK kinase inhibitors have substantially improved survival in advanced melanoma; however, therapeutic resistance and severe toxicities underscore the ongoing need for alternative strategies. Here, we evaluate the clinical utility of multi-omic profiling, biomarker-stratified...
T. Lowinus, V. Schipperges, P. Metzger et al.· npj Precision Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.